Due to the difficulty in vaccine research and development, based on the international experience of African swine fever prevention and control, the primary task at present is to improve the comprehensive prevention and control measures of African swine fever and strengthen the research on new immunization technologies.
The vast majority of African swine fever will be cured by isolation treatment of relevant departments, but the treatment still depends on a pharmaceutical composition for preventing and treating African swine fever and the application of its extract, injection and patented technology. Recently, on August 9, the International Intellectual Property Office announced this patent. The patent application number is 201910529164.6, and the patentee is Xu Qitai. This patent has a very good therapeutic effect on African swine fever, and can also prevent African swine fever virus, which fundamentally solves the African swine fever virus.
The raw materials involved in the patent technology of the invention are: Ganoderma lucidum 10-30 parts, Jindiluo 4- 12 parts, beef tendon fruit 4- 12 parts, areca nut 30-50 parts, Callicarpa nudiflora 4- 12 parts, and Chinese yam 4-/kloc-. Its efficacy is not just lip service, but the result obtained from the actual experiment.
First, some time ago, African swine fever appeared in major farms. The experimental team selected a batch of 420 pigs of the same size and age from a farm, and they have been diagnosed with African swine fever. These pigs will die on the eighth day if they are not treated with drugs. However, after injecting this drug, the survival rate of these pigs is as high as 90%. These cured pigs recovered their appetite and normal growth and development. Therefore, it is concluded that the patented technology can be used to prepare drugs for treating African swine fever virus.